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In 1999, Engelen and coworkers investigated colonization in Amsterdam among 259 children attending 16
day-care centers (DCCs) and among 276 children who did not attend day-care centers (NDCCs). A 1.6- to 3.4-
fold increased risk for nasopharyngeal colonization was observed in children attending DCCs compared with
NDCC children, while no difference in antibiotic resistance was found between groups. The serotype and
genotype distributions of 305 nasopharyngeal Streptococcus pneumoniae isolates of the latter study were
investigated. The predominant serotypes in both the DCC and the NDCC groups included 19F (19 and 18%,
respectively), 6B (14 and 16%, respectively), 6A (13 and 7%, respectively), 23F (9 and 7%, respectively), and 9V
(7 and 7%, respectively). The theoretical vaccine coverage of the 7-valent conjugate vaccine was 59% for the
DCC children and 56% for the NDCC group. Genetic analysis of the pneumococcal isolates revealed 75%
clustering among pneumococci isolated from DCC attendees versus 50% among the NDCC children. The
average pneumococcal cluster size in the DCC group was 3.8 and 4.6 isolates for two respective sample dates
(range, 2 to 13 isolates per cluster), while the average cluster size for the NDCC group was 3.0 (range, 2 to 6
isolates per cluster). Similar to observations made in other countries, these results indicate a higher risk for
horizontal spread of pneumococci in Dutch DCCs than in the general population. This study emphasizes the
importance of molecular epidemiological monitoring before, during, and after implementation of pneumococ-
cal conjugate vaccination in national vaccination programs for children.
Streptococcus pneumoniae is worldwide one of the major
causes of severe infections such as meningitis, septicemia, and
respiratory tract infections. In addition, S. pneumoniae is, to-
gether with Moraxella catarrhalis and Haemophilus influenzae, a
dominant pathogen in middle ear infections and sinusitis. Risk
groups for pneumococcal infections are young children under
the age of 2 years, elderly people, and immunocompromised
patients (1).
Pneumococci are often part of the nasopharyngeal flora;
probably all humans are colonized with this organism at least
once early in life. The risk of pneumococcal colonization is
high, especially under conditions with crowding, such as day-
care centers (DCCs), nursing homes, hospitals, and jails (16,
22, 23). A strong relation between carriage and middle ear
infections has been found, but the association between coloni-
zation and invasive disease has not been confirmed (11, 31).
The emergence of penicillin- and multidrug-resistant pneu-
mococci has been observed in various countries over the last
decade. In some countries and populations, up to 60% of the
pneumococcal isolates are resistant to one or more antibiotics
(3, 12, 17). A significant proportion of pneumococcal resis-
tance is the result of the worldwide spread of a limited number
of multidrug-resistant clones (4, 14, 30, 35). Carriage of organ-
isms with decreased antibiotic susceptibility is associated with
young age, female sex, winter season, and exposure to antimi-
crobial drugs during the previous month (37).
Children attending DCCs have several risk factors for car-
riage, i.e., young age, crowding, and frequent usage of antimi-
crobial agents. Furthermore, it is believed that DCCs may be a
global reservoir for multidrug-resistant pneumococci (27).
Therefore, prevention of carriage and infection with S. pneu-
moniae in these risk groups will become an important tool in
the battle against (antibiotic-resistant) S. pneumoniae.
Prevention of infections caused by S. pneumoniae and of
spread of this pathogen is an important goal of an effective
vaccine. Therefore, new vaccines have been developed that are
also immunogenic in risk groups, such as young children, the
elderly, and immunocompromised patients. Results with these
conjugate vaccines, containing polysaccharides from up to 11
different serotypes conjugated to a protein carrier (tetanus-
diphtheria toxoid-Hib protein or meningococcal outer mem-
brane protein), are promising (6, 9, 21, 28, 29). Recently, one
of these vaccines, the 7-valent pneumococcal conjugate vaccine
from Wyett Lederle, has been approved by the Department of
Health and Human Services in the United States and the
European Agency for the Evaluation of Medicine for Europe.
The introduction of the conjugate vaccines underscores the
need for detailed and long-term epidemiological surveillance
of S. pneumoniae in the target groups in order to calculate the
theoretical vaccine coverage and to evaluate the (long-term)
effects of large-scale introduction of this vaccine in the general
population by using serological and molecular techniques. So
* Corresponding author. Mailing address: Laboratory of Pediatrics,
Room Ee1500, Erasmus University Rotterdam, P.O. Box 1738, 3000
DR Rotterdam, The Netherlands. Phone: 31-10-4087998. Fax: 31-10-
4089486. E-mail: hermans@kgk.fgg.eur.nl.
3316
far, no data are available on the molecular epidemiology of
S. pneumoniae carriage in young children in The Netherlands.
In 1999, a study was performed in Amsterdam, The Neth-
erlands, among 259 children attending 16 DCCs and 276 chil-
dren who did not attend day-care centers (NDCC). We inves-
tigated nasopharyngeal carriage rates and susceptibility
to antibiotics of the nasopharyngeal flora. Carriage rates for
S. pneumoniae, M. catarrhalis, and H. influenzae of 37, 48, and
11%, respectively, were observed in the NDCC group. In-
creased risks of 1.6, 1.7, and 3.4 for carriage of S. pneumoniae,
M. catarrhalis, and H. influenzae, respectively, were observed
among DCC attendees. Finally, DCC attendees were ill more
frequently and used more antibiotics than the controls. Similar
to earlier surveillance data from The Netherlands (20), only
2% of the pneumococcal isolates showed reduced susceptibil-
ity to erythromycin and no penicillin resistance was found
(P. Peerbooms, M. Engelen, A. van Belkum, and R. Coutinho,
11th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. 8, 2001).
These results are in contrast to data from previous DCC stud-
ies in other countries, where antibiotic resistance among pneu-
mococcal isolates was high, associated with previous antibiotic
consumption, and correlated to increased spread of drug-re-
sistant pneumococci among DCC attendees (2, 5, 24, 33, 37).
Because drug resistance among pneumococci is negligible in our
study group, we hypothesized that crowding, which is also a risk
factor for nasopharyngeal carriage, is playing an important role
in facilitating the transmission of bacteria among children in
DCCs. To obtain insight in the transmission of pneumococci in
children, the molecular epidemiology of the pneumococcal
isolates collected from both the general population and DCCs
was investigated by serotyping and genotyping.
MATERIALS AND METHODS
Bacterial sampling. S. pneumoniae strains were isolated from the nasopharyn-
ges of 259 children, aged 3 to 36 months, attending 16 DCCs in Amsterdam, The
Netherlands, from January to March 1999. All children were sampled twice, with
a time interval of 4 weeks. In the same period, an additional 276 children from
three well-baby clinics in Amsterdam, aged 3 to 36 months, who did not attend
DCCs were evaluated for S. pneumoniae carriage (P. Peerbooms et al., 11th Eur.
Cong. Clin. Microbiol. Infect. Dis., 2001). Nasopharyngeal samples were ob-
tained with a dacron pernasal swab (Medical Wire & Equipment Co., Wiltshire,
England). The swabs were transported in Amies transport medium to the Mi-
crobiology Laboratory of the Municipal Health Service (Amsterdam, The Neth-
erlands), immediately plated on 5% sheep blood agar plates, and grown over-
night at 36°C in a CO2-enriched atmosphere. S. pneumoniae isolates were
identified according to standard microbiological procedures (18). Molecular
analyses were performed on all the pneumococcal isolates that were available for
use, i.e., 115 and 129 strains collected from the 16 DCCs on the two occasions,
respectively, and 61 strains collected from the NDCC children.
Serotyping. Pneumococci were serotyped by the capsular quellung method
(Quellung reaction) and observed microscopically using commercially available
antisera (Statens Seruminstitut, Copenhagen, Denmark).
RFEL. Typing of the 305 pneumococcal strains by restriction fragment end
labeling (RFEL) analysis was performed as described by Van Steenbergen et al.
(36) and as adapted by Hermans et al. (15). Briefly, purified pneumococcal DNA
was digested by the restriction enzyme EcoRI. The DNA restriction fragments
were end labeled at 72°C with [-32P]dATP using DNA polymerase (Goldstar;
Eurogentec, Seraing, Belgium). The radiolabeled fragments were denatured and
separated electrophoretically on a 6% polyacrylamide sequencing gel containing
8 M urea. Subsequently, the gel was transferred onto filter paper, vacuum dried
(HBI, Saddlebrook, N.Y.), and exposed for variable lengths of time at room
temperature to ECL Hyperfilms (Amersham, Little Chalfont, United Kingdom).
Computer-assisted analysis of RFEL banding patterns. The RFEL types were
analyzed using the Windows version of the Gelcompar software (version 4;
Applied Maths, Kortrijk, Belgium) after imaging the RFEL autoradiograms
using the Image Master DTS (Pharmacia Biotech, Uppsala, Sweden). For this
purpose, DNA fragments in the molecular weight range of 160 to 400 bp were
explored. The DNA banding patterns were normalized using pneumococcus-
specific bands present in the RFEL banding patterns of all strains. Comparison
of the banding patterns was performed by unweighted pair group method using
arithmetic averages (25) and the Jaccard similarity coefficient applied to peaks
(32). Computer-assisted analysis and methods and algorithms used in this study
were carried out according to the instructions of the manufacturer of Gelcompar.
A tolerance of 1.2% in band position was applied during comparison of the DNA
patterns. For evaluation of the genetic relatedness of the isolates, we used the
following definitions: score of 1, strains of the particular RFEL type are consid-
ered 100% identical by RFEL analysis; score of 2, the RFEL cluster represents
a group of RFEL types that differs in only one band (95% genetic relatedness);
score of 3, the RFEL lineage represents a group of RFEL types that differs in less
than four bands (85% genetic relatedness).
The genotypes of the pneumococcal isolates were also compared with an
international collection of pneumococcal strains representing about 320 distinct
RFEL types originating from 17 different countries in America, Europe, Africa,
and Asia (M. Sluijter, unpublished observations), including the 16 international
clones described by the Pneumococcal Epidemiology Network (http://www.wits
.ac.za/pmen/pmen.htm).
Statistical analysis. For statistical analysis of the results, the Fisher exact test
was used.
RESULTS
We investigated the serotypes of 244 DCC isolates and 61
NDCC isolates (Table 1). The predominant serotypes in both
the DCC and NDCC groups were the serotypes 19F (19 and
18%, respectively), 6B (14 and 16%, respectively), 6A (13 and
7%, respectively), 23F (9 and 7%, respectively), 9V (7 and 7%,
respectively), and 14 (7 and 5%, respectively). The serotypes
19F, 6B, 23F, 9V, and 14 are covered by the 7-valent pneumo-
coccal conjugate vaccine. The other two serotypes covered by
the 7-valent conjugate vaccine are serotypes 4 and 18C. No
children were colonized with vaccine type 4, and only 1 to 3%
of the children were colonized with vaccine serotype 18. The
theoretical vaccine coverages of the 7-valent conjugate vaccine
are 59% for the DCC group and 57% for the NDCC group.
The theoretical vaccine coverage of the 11-valent conjugate
vaccine, in which the additional capsular types 1, 3, 5, and 7F
are included, is 62% for both the DCC and NDCC groups.
TABLE 1. Contribution of vaccine serotypes to carriage
of S. pneumoniae in Dutch infants
Serotype













7-valent conjugate vaccine (4, 6B, 9V, 14,
18C, 19F, and 23F)
59 57
7-valent conjugate vaccine (including 6A) 72 64
11-valent conjugate vaccine (7-valent  1,
3, 5, and 7F)
62 62
11-valent conjugate vaccine (including 6A) 75 70
a Average percentages were calculated from the two sampling dates.
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Genotyping of the 305 pneumococcal isolates from this
study was performed by RFEL analysis. The 61 isolates from
the NDCC children showed 50 different genotypes; 50% of the
strains represented 10 distinct genetic clusters. Cluster sizes in
the NDCC group ranged from two to six strains per cluster
with an average cluster size of 3.0. The DCC group displayed
66 and 75 different genotypes at the first and second sampling
dates, respectively. Seventy-five percent of the strains from
both the first and the second sampling dates represented 24
and 20 clusters, respectively. This percentage differed signifi-
cantly from the 50% genetic clustering observed in the NDCC
group (P  0.01). Cluster sizes within the individual sampling
data ranged from 2 to 13 strains, with an average cluster size of
3.8 and 4.6 for the two sampling dates, respectively (Fig. 1).
The majority of the clusters in both the DCC group (29 of 44
clusters) and the NDCC group (8 of 10 clusters) displayed a
serotype covered by the 7-valent conjugate vaccine, including
the cross-protective serotype 6A (Fig. 1). We also investigated
carriage turnover in the DCC group, defined as the percentage
of children with positive pneumococcal samples at both sam-
pling dates that changed genotypes within the 4-week interval
between sampling dates. A total of 209 of 259 children in the
DCC group were carrying a pneumococcus on the nasopharynx
at least once. Of the 259 children, 107 were carrying pneumo-
cocci on the nasopharynx at both sampling dates. The isolates
from 69 children who were identified as being colonized by
S. pneumoniae at both sampling dates were available for mo-
lecular analysis. Forty-four of these 69 children had changed
genotypes between the two sampling dates, i.e., a carriage turn-
over of 64%.
Comparison of the RFEL data with the 16 international
clones described by the Pneumococcal Epidemiology Network
demonstrated that six isolates (10%) of the NDCC group were
identical to the clones Taiwan19F-14 (1 isolate), France9V-3 (3
isolates), Slovakia14-10 (1 isolate), and Tennessee23F-4 (1 iso-
late), whereas 25 of the isolates from the DCC group (10%)
belonged to the clones France9V-3 (15 isolates), Slovakia14-10
(6 isolates), and Tennessee23F-4 (4 isolates). All but one of the
isolates were susceptible to the antibiotics penicillin, tetracy-
cline, erythromycin, and cotrimoxazole, in contrast to the anti-
biotic resistance patterns of their genetically homologous clones.
Only the isolate identical to clone Taiwan19F-14 was resistant
to erythromycin (Peerbooms et al., 11th Eur. Cong. Clin. Mi-
crobiol. Infect. Dis., 2001).
DISCUSSION
In The Netherlands, the prevalence of pneumococcal colo-
nization in the pediatric population was found to be 58% in
DCC attendees versus 37% in the NDCC group, i.e., a 1.6-fold
higher risk of pneumococcal colonization in DCC attendees
compared to age-matched NDCC children (Peerbooms et al.,
11th Eur. Cong. Clin. Microbiol. Infect. Dis., 2001). Known
risk factors for carriage of S. pneumoniae are young age,
FIG. 1. Number and distribution of pneumococcal isolates with unique genotypes or genetically clustered isolates from both the NDCC
children and the DCC attendees. The clustered isolates are further grouped into separate clusters. Cluster sizes are depicted on the right; clusters
representing conjugate-vaccine serotypes are depicted in gray, and nonvaccine serotypes are depicted in white. DCC1 and DCC2 refer to the two
different sampling dates.
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crowding, and antibiotic usage. Since only 2% of the pneumo-
coccal isolates were resistant to erythromycin and no resistance
to the antibiotics penicillin, cotrimoxazole, or tetracycline was
found, crowding is presumed to be the most important con-
tributor to the difference in carriage seen in this study. We
hypothesize that crowding facilitates horizontal transfer of bac-
teria from one child to another. Therefore, we investigated the
molecular epidemiology of 305 pneumococcal isolates from
this study. Both the DCC group and the NDCC group showed
a serotype distribution comparable to what is found in many
other countries, such as Israel, Finland, Canada, and South
Africa (6, 10, 16, 19, 34). The most predominant serotypes
were 19F (19 and 18% in DCC and NDCC attendees, respec-
tively), 6B (14 and 16%, respectively), 6A (13 and 7%, respec-
tively), 23F (9 and 7%, respectively), and 9V (7 and 7%, re-
spectively). This serotype distribution implicates a theoretical
coverage of 57 to 59% by the 7-valent conjugate vaccine. The
additive value of an 11-valent conjugate vaccine is only 3 to 5%
(62% total coverage for both study groups). An additive cross-
protective effect is expected at least for serotype 6A (26), which
increases the theoretical coverage of the 7-valent conjugate
vaccine to 64% for the NDCC group and to 72% for the DCC
group. It is unknown whether a cross-protective effect can be
expected for the serotypes 19A, 23A, and 23B (13, 26, 38).
With respect to the theoretical vaccine coverage, the long-term
effect of large-scale implementation of the conjugate vaccine
for the Dutch pediatric population remains unknown. Eskola
et al. have found a similar serotype distribution before vacci-
nation with the 7-valent pneumococcal conjugate vaccine and
a shift towards nonvaccine serotypes causing middle ear infec-
tion after vaccination (10). Such a shift in distribution after
conjugate vaccination was also observed among nasopharyn-
geal carriage isolates (7, 8, 19; S. K. Obaro, R. A. Adegbola,
W. A. Banya, and B. M. Greenwood, Letter, Lancet 348:271–
272, 1996). Therefore, it is concluded that a shift in distribution
towards nonvaccine serotypes will reduce the efficacy of con-
jugate vaccination with respect to carriage and disease.
In the DCC group, 75% of the pneumococci represented
genetic clusters, in contrast to 50% in the NDCC group. These
molecular epidemiological data suggest augmented spread of
pneumococci among DCC attendees compared to the NDCC
group. In addition, the average cluster size for the first and
second sampling dates in the DCC group were 3.8 and 4.6,
respectively, with a range of 2 to 13 isolates per cluster, com-
pared to 3.0 for the control group with a range of 2 to 6 isolates
per cluster (Fig. 1). These data show larger clusters in the DCC
group, which supports the hypothesis that pneumococci are
spread more frequently by horizontal transfer between DCC
attendees than among NDCC attendees. A carriage turnover
of 64% in the DCC children with two positive pneumococcal
isolates at both sampling dates was observed. At present, no
carriage turnover data are available for the NDCC population.
Whether the genotype shift in the DCC population is due to
recolonization of the nasopharyngeal niche by new genotypes
or whether it is due to unmasking of genotypes which were
already present but not detected as a result of the abundant
presence of other genotypes needs to be further investigated.
The RFEL patterns of both the DCC group and the NDCC
group were compared with the 16 international (multidrug-
resistant) clones described by the Pneumococcal Epidemiology
Network. Twenty-five isolates (10%) in the DCC group were
homologous to 3 of the reference clones (100% identical),
whereas 6 isolates (10%) in the NDCC group matched with 4
of these clones. In contrast to the multidrug-resistant reference
clones, all isolates but one were fully susceptible to penicillin,
erythromycin, and cotrimoxazole. The resistant isolate, identi-
cal to the clone Taiwan19F-14, had reduced susceptibility to
erythromycin only, whereas the reference clone was resistant
to erythromycin, penicillin, and tetracycline. These results sug-
gest that these Dutch isolates represent members of the an-
cestor lineages of the resistant reference clones. The overall
absence of resistant pneumococcal strains in The Netherlands
may be explained by the restricted use of antibiotics in general
compared to that in many other countries.
In conclusion, an increased frequency of horizontal spread
of S. pneumoniae strains was shown in DCCs. At least 56% of
the nasopharyngeal pneumococcal isolates would be theoreti-
cally covered by a 7-valent conjugate vaccine. Furthermore, the
majority of the horizontal spreading genotypes (70 to 80%)
express capsular types that are covered by the conjugate vac-
cine. These data indicate that implementation of the pneumo-
coccal conjugate vaccine in the near future in Dutch infants,
and especially in risk groups like DCC attendees, should be
considered. Importantly, to investigate the long-term efficacy
of the vaccine against pneumococcal infections, detailed mo-
lecular epidemiological monitoring of pneumococcal coloniza-
tion and infection is required.
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